Mark Hollywood Biography and Net Worth

COO of Zymeworks

Mr. Hollywood joined Zymeworks in 2019 and currently serves as our Executive Vice President and Chief Operating Officer. Mr. Hollywood brings over 25 years of experience in the biopharmaceutical industry, most recently as Vice President and Head of ZymoGenetics (a Bristol-Myers Squibb company), where he oversaw biologics development, manufacturing, quality, and supply chain operations. He joined ZymoGenetics in 2010 and led technical operations for a portfolio of clinical and commercial products, and was responsible for building and managing a multi-host drug substance manufacturing facility. Mr. Hollywood brings a wealth of experience in operations management, having held positions of increasing responsibility in process science, manufacturing, quality, and regulatory compliance at organizations including Amgen, Dendreon and Centeon (a Rhone-Poulenc Rorer and Hoescht company). Mr. Hollywood has a Bachelor of Science degree in Biological Sciences from Western Illinois University.

What is Mark Hollywood's net worth?: The estimated net worth of Mark Hollywood is at least $3.14 million as of January 12th, 2026. Hollywood owns 132,913 shares of Zymeworks stock worth more than $3,143,392 as of February 24th. This net worth estimate does not reflect any other assets that Hollywood may own. Learn More about Mark Hollywood's net worth.
How do I contact Mark Hollywood?: The corporate mailing address for Hollywood and other Zymeworks executives is 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN, DE, 19709. Zymeworks can also be reached via phone at (302) 274-8744 and via email at [email protected]. Learn More on Mark Hollywood's contact information.
Has Mark Hollywood been buying or selling shares of Zymeworks?: During the past quarter, Mark Hollywood has sold $138,740.40 of Zymeworks stock. Most recently, Mark Hollywood sold 6,120 shares of the business's stock in a transaction on Monday, January 12th. The shares were sold at an average price of $22.67, for a transaction totalling $138,740.40. Following the completion of the sale, the chief operating officer now directly owns 132,913 shares of the company's stock, valued at $3,013,137.71. Learn More on Mark Hollywood's trading history.
Who are Zymeworks' active insiders?: Zymeworks' insider roster includes Kenneth Galbraith (Chair & CEO), Mark Hollywood (COO), Neil Josephson (Insider), Neil Klompas (CFO), Paul Moore (Chief Scientific Officer), Kathryn O'Driscoll (Insider), James Priour (Insider), Jeffrey Smith (Executive Vice President and Chief Medical Officer), and Ali Tehrani (CEO). Learn More on Zymeworks' active insiders.
Are insiders buying or selling shares of Zymeworks?: During the last year, Zymeworks insiders bought shares 13 times. They purchased a total of 1,405,768 shares worth more than $16,773,032.28. During the last year, insiders at the sold shares 8 times. They sold a total of 187,933 shares worth more than $4,673,716.04. The most recent insider tranaction occured on January, 12th when CEO Kenneth Galbraith sold 30,424 shares worth more than $689,712.08. Insiders at Zymeworks own 33.5% of the company. Learn More about insider trades at Zymeworks.
Information on this page was last updated on 1/12/2026.

Mark Hollywood Insider Trading History at Zymeworks

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/12/2026	Sell	6,120	$22.67	$138,740.40	132,913

Mark Hollywood Buying and Selling Activity at Zymeworks

Zymeworks Company Overview

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Today's Range

Now: $23.63

$22.80

$23.68

50 Day Range

MA: $24.19

$22.02

$27.62

2 Week Range

Now: $23.63

$9.03

$28.49

Volume

445,321 shs

Average Volume

777,076 shs

Market Capitalization

$1.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25